Veraxa Collaborates With ATUM on Cell Line Development for BiTAC T-Cell Engager Program

MT Newswires Live

Jul 02

Veraxa Biotech (VRXA) said Thursday it has engaged US contract research organization ATUM to begin cell line development for its lead BiTAC T-cell engager program.

The company said ATUM will support the generation of stable clonal cell lines using its Leap-In Transposase technology.

The company said the cell lines will be used throughout CMC development, including early process, analytical testing, formulation work, and production of material for nonclinical studies.

Veraxa said its BiTAC-TCE platform is designed to improve the safety of T-cell engager therapies by activating T-cells only when two tumor markers are present on the same cell, reducing the risk of attacking healthy tissue.

Shares of Veraxa Biotech were up more than 3% in premarket activity Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2648040085"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2648040085\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2648040085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648040085","market":"hk","top_or_hot":-1,"title":"Veraxa Collaborates With ATUM on Cell Line Development for BiTAC T-Cell Engager Program","media":"MT Newswires Live","content":"<html><body><p> Veraxa Biotech (VRXA) said Thursday it has engaged US contract research organization ATUM to begin cell line development for its lead BiTAC T-cell engager program.</p><p>The company said ATUM will support the generation of stable clonal cell lines using its Leap-In Transposase technology.</p><p>The company said the cell lines will be used throughout CMC development, including early process, analytical testing, formulation work, and production of material for nonclinical studies.</p><p>Veraxa said its BiTAC-TCE platform is designed to improve the safety of T-cell engager therapies by activating T-cells only when two tumor markers are present on the same cell, reducing the risk of attacking healthy tissue.</p><p>Shares of Veraxa Biotech were up more than 3% in premarket activity Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veraxa Collaborates With ATUM on Cell Line Development for BiTAC T-Cell Engager Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeraxa Collaborates With ATUM on Cell Line Development for BiTAC T-Cell Engager Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-02 19:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Veraxa Biotech (VRXA) said Thursday it has engaged US contract research organization ATUM to begin cell line development for its lead BiTAC T-cell engager program.</p><p>The company said ATUM will support the generation of stable clonal cell lines using its Leap-In Transposase technology.</p><p>The company said the cell lines will be used throughout CMC development, including early process, analytical testing, formulation work, and production of material for nonclinical studies.</p><p>Veraxa said its BiTAC-TCE platform is designed to improve the safety of T-cell engager therapies by activating T-cells only when two tumor markers are present on the same cell, reducing the risk of attacking healthy tissue.</p><p>Shares of Veraxa Biotech were up more than 3% in premarket activity Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRXA","symbol_name":"Veraxa Biotech Holding AG","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2648040085","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648040085","pubTimestamp":1782992371,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Veraxa Biotech  said Thursday it has engaged US contract research organization ATUM to begin cell line development for its lead BiTAC T-cell engager program.The company said ATUM will support the generation of stable clonal cell lines using its Leap-In Transposase technology.The company said the cell lines will be used throughout CMC development, including early process, analytical testing, formulation work, and production of material for nonclinical studies.Veraxa said its BiTAC-TCE platform is designed to improve the safety of T-cell engager therapies by activating T-cells only when two tumor markers are present on the same cell, reducing the risk of attacking healthy tissue.Shares of Veraxa Biotech were up more than 3% in premarket activity Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRXA":"Veraxa Biotech Holding AG","BK4139":"生物科技"},"translate_title":"Veraxa与ATUM合作开发BiTAC T细胞接合器项目的细胞系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRXA":1},"content_text":"Veraxa Biotech (VRXA) said Thursday it has engaged US contract research organization ATUM to begin cell line development for its lead BiTAC T-cell engager program.The company said ATUM will support the generation of stable clonal cell lines using its Leap-In Transposase technology.The company said the cell lines will be used throughout CMC development, including early process, analytical testing, formulation work, and production of material for nonclinical studies.Veraxa said its BiTAC-TCE platform is designed to improve the safety of T-cell engager therapies by activating T-cells only when two tumor markers are present on the same cell, reducing the risk of attacking healthy tissue.Shares of Veraxa Biotech were up more than 3% in premarket activity Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}